Pfizer Retained Earnings (Accumulated Deficit) 2012-2026 | PFE
Pfizer retained earnings (accumulated deficit) from 2012 to 2026. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Pfizer retained earnings (accumulated deficit) for the quarter ending March 31, 2026 were $121.150B, a 0.08% increase year-over-year.
- Pfizer retained earnings (accumulated deficit) for 2024 were $116.725B, a 1.38% decline from 2023.
- Pfizer retained earnings (accumulated deficit) for 2023 were $118.353B, a 5.81% decline from 2022.
- Pfizer retained earnings (accumulated deficit) for 2022 were $125.656B, a 21.53% increase from 2021.
|
Pfizer Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024 | $116,725 |
| 2023 | $118,353 |
| 2022 | $125,656 |
| 2021 | $103,394 |
| 2020 | $90,392 |
| 2019 | $97,670 |
| 2018 | $89,554 |
| 2017 | $85,291 |
| 2016 | $71,774 |
| 2015 | $71,993 |
| 2014 | $72,176 |
| 2013 | $69,732 |
| 2012 | $54,240 |
| 2011 | $46,210 |
|
Pfizer Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2025-09-30 | $121,150 |
| 2025-06-30 | $117,609 |
| 2025-03-31 | $119,590 |
| 2024-12-31 | $116,725 |
| 2024-09-30 | $121,059 |
| 2024-06-30 | $116,596 |
| 2024-03-31 | $121,318 |
| 2023-12-31 | $118,353 |
| 2023-09-30 | $126,411 |
| 2023-06-30 | $128,796 |
| 2023-03-31 | $131,102 |
| 2022-12-31 | $125,656 |
| 2022-09-30 | $122,967 |
| 2022-06-30 | $116,608 |
| 2022-03-31 | $111,193 |
| 2021-12-31 | $103,394 |
| 2021-09-30 | $102,252 |
| 2021-06-30 | $96,346 |
| 2021-03-31 | $95,158 |
| 2020-12-31 | $90,392 |
| 2020-09-30 | $100,284 |
| 2020-06-30 | $100,203 |
| 2020-03-31 | $101,000 |
| 2019-12-31 | $97,670 |
| 2019-09-30 | $100,113 |
| 2019-06-30 | $94,440 |
| 2019-03-31 | $93,388 |
| 2018-12-31 | $89,554 |
| 2018-09-30 | $91,995 |
| 2018-06-30 | $89,860 |
| 2018-03-31 | $89,961 |
| 2017-12-31 | $85,291 |
| 2017-09-30 | $75,043 |
| 2017-06-30 | $74,107 |
| 2017-03-31 | $74,847 |
| 2016-12-31 | $71,774 |
| 2016-09-30 | $72,846 |
| 2016-06-30 | $73,350 |
| 2016-03-31 | $74,971 |
| 2015-12-31 | $71,993 |
| 2015-09-30 | $74,019 |
| 2015-06-30 | $73,620 |
| 2015-03-31 | $74,471 |
| 2014-12-31 | $72,176 |
| 2014-09-30 | $74,292 |
| 2014-06-30 | $71,627 |
| 2014-03-31 | $72,028 |
| 2013-12-31 | $69,732 |
| 2013-09-30 | $70,381 |
| 2013-06-30 | $67,628 |
| 2013-03-31 | $56,972 |
| 2012-12-31 | $54,240 |
| 2012-09-30 | $51,256 |
| 2012-06-30 | $47,904 |
| 2012-03-31 | $48,124 |
| 2011-12-31 | $46,210 |
| 2011-09-30 | $48,121 |
| 2011-06-30 | $44,320 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |